Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Asthma inhaler enerzair under Real-World watch

NCT ID NCT05274425

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Apr 20, 2026 · Last updated May 23, 2026 · Updated 5 times

Summary

This study is a required safety check for the asthma inhaler Enerzair, already approved for use. It will follow 600 adults with asthma for 24 weeks to see how well the drug works and what side effects occur in everyday medical practice. The goal is to confirm the drug's safety and effectiveness outside of controlled clinical trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Novartis Investigative Site

    RECRUITING

    Daegu, Dalseo gu, 42602, South Korea

  • Novartis Investigative Site

    RECRUITING

    Wŏnju, Gangwon-do, 26426, South Korea

  • Novartis Investigative Site

    COMPLETED

    Bucheon-si, Gyeonggi-do, 14584, South Korea

  • Novartis Investigative Site

    RECRUITING

    Bundang Gu, Gyeonggi-do, 13620, South Korea

  • Novartis Investigative Site

    COMPLETED

    Goyang-si, Gyeonggi-do, 10475, South Korea

  • Novartis Investigative Site

    RECRUITING

    Jeonju, Jeollabuk-do, 561 712, South Korea

  • Novartis Investigative Site

    COMPLETED

    Suncheon, Jeollanam-do, 540-719, South Korea

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Cheongju-si, North Chungcheong, 28644, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Seoul, 06351, South Korea

  • Novartis Investigative Site

    RECRUITING

    Busan, 49201, South Korea

  • Novartis Investigative Site

    RECRUITING

    Daegu, 705703, South Korea

  • Novartis Investigative Site

    RECRUITING

    Gwangju, 501171, South Korea

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Gyeonggi-do, 14353, South Korea

  • Novartis Investigative Site

    RECRUITING

    Gyeongsangnam Do, 630-522, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 04763, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 06273, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 2447, South Korea

Conditions

Explore the condition pages connected to this study.

ASTHMA